1-3 of 3
Amanda Copeland, MSN
Close
Sort by
Journal Articles

Safety and Efficacy of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) in Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma,

Anas Younes, MD, Amanda Copeland, MSN, Michelle A. Fanale, MD, Luis Fayad, MD, Jorge E Romaguera, MD, Larry W Kwak, MD, PhD, Sattva S. Neelapu, MD, Fredrick Hagemeister, MD, Barbara Pro, MD, Silvana de Castro Faria, MD, Yuan Ji, PhD, Donald Berry, Daniela Buglio, MD, PhD, L. Jeffrey Medeiros, MD
Journal: Blood
Blood (2011) 118 (21): 3718.
https://doi.org/10.1182/blood.V118.21.3718.3718
Published: 2011
Journal Articles

Improving T Cell Therapy for Relapsed EBV-Negative Hodgkin's Lymphoma by Targeting Upregulated MAGE-A4

Conrad Russell Y. Cruz, MD, Ulrike Gerdemann, MD, Ann M. Leen, PhD, Jessica A. Shafer, MD, Stephanie Ku, BS, Benjamin Tzou, BS, Terzah M. Horton, MD, PhD, Amanda Copeland, MSN, Anas Younes, MD, Cliona M. Rooney, PhD, Helen E. Heslop, MD, Catherine M. Bollard, MD
Journal: Blood
Blood (2011) 118 (21): 1658.
https://doi.org/10.1182/blood.V118.21.1658.1658
Published: 2011
Journal Articles

Phase I/II Study of the Novel Combination of Panobinostat (LBH589) and Everolimus (RAD001) In Relapsed/Refractory Hodgkin and Non-Hodgkin Lymphoma

Anas Younes, MD, Amanda Copeland, MSN, Michelle A. Fanale, MD, Fredrick Hagemeister, MD, Luis Fayad, MD, Barbara Pro, MD, Silvana C. Faria, MD, PhD, Yuan Ji, PhD, L. Jeffrey Medeiros, MD, Donald A Berry, PhD, Daniela Buglio, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 3964.
https://doi.org/10.1182/blood.V116.21.3964.3964
Published: 2010